One of the most successful drugs ever produced is Rituximab. Rituximab is an antibody that binds CD20 and eliminates B-cells. Today multiple companies are producing generic Rituximab.
Recently, Centrose discovered that Rituximab interacts with an ion pump. This discovery led to EDC9. EDC9 acts on this pump when found on the surface of B-cells and greatly enhances the activity of Rituximab. Unlike all other drugs acting on CD20, EDC9 potently kills cells expressing high or low levels of CD20 and does not harm other cells. Because the affect is so specific and potent, Centrose depressed the complement-directed cytotoxicity affect of Rituximab to lessen the risk of EDC9 infusion reactions, a life-threatening side effect of Rituximab. Studies in primates showed that EDC9 clears all detectable CD20 expressing cells without adverse effects. Currently EDC9 is in the manufacturing stage of development and expected to reach human testing in 2019.